

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN

IDRAPARINUX SODIUM

PRONUNCIATION

eye dra par' in ux


THERAPEUTIC CLAIM

antithrombotic, indirect, selective, synthetic factor Xa inhibitor

CHEMICAL NAMES

- 1) α -D-glucopyranoside, methyl *O*-2,3,4-tri-*O*-methyl-6-*O*-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-*O*-2,3-di-*O*-methyl- β -D-glucopyranuronosyl-(1 \rightarrow 4)-*O*-2,3,6-tri-*O*-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-*O*-2,3-di-*O*-methyl- α -L-idopyranuronosyl-(1 \rightarrow 4)-,2,3,6-tris(hydrogen sulfate), nonasodium salt
- 2) methyl (sodium 2,3,4-tri-*O*-methyl-6-*O*-sulfonato- α -D-glucopyranosyl)-(1 \rightarrow 4)-(sodium 2,3-di-*O*-methyl- β -D-glucopyranosylurate)-(1 \rightarrow 4)-(trisodium 2,3,6-tri-*O*-sulfonato- α -D-glucopyranosyl)-(1 \rightarrow 4)-(sodium -2,3-di-*O*-methyl- α -L-idopyranosyluronate)-(1 \rightarrow 4)-(trisodium 2,3,6-tri-*O*-sulfonato- α -D-glucopyranoside)

STRUCTURAL FORMULA



MOLECULAR FORMULA

$C_{38}H_{55}Na_9O_{49}S_7$

MOLECULAR WEIGHT

1727.2

TRADEMARK

Unknown as yet

MANUFACTURER

Sanofi-Synthelabo

CODE DESIGNATION

SANORG34006

CAS REGISTRY NUMBER

149920-56-9